{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:30:39Z","timestamp":1793406639113,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":55,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015383","name":"Stichting voor Lever- en Maag-Darm Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.100912","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:30:24Z","timestamp":1772559024000},"page":"100912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Fibrotic Metabolic Dysfunction\u2013Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2333-1182","authenticated-orcid":false,"given":"Laurens A.","family":"van Kleef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesut","family":"Savas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Pustjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Theel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth F.C.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Labenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem P.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2026.100912_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gastha.2026.100912_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2026.100912_bib3","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal Arun","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2026.100912_bib4","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.gastha.2026.100912_bib5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2023.04.035","article-title":"A global research priority agenda to advance public health responses to fatty liver disease","volume":"79","author":"Lazarus","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastha.2026.100912_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.2026","article-title":"Prescription fills for semaglutide products by payment method","volume":"5","author":"Scannell","year":"2024","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.gastha.2026.100912_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57232","article-title":"Longitudinal analysis of obesity drug use and public awareness","volume":"8","author":"Berning","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.gastha.2026.100912_bib8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jama.2024.3073","article-title":"State coverage and reimbursement of antiobesity medications in medicaid","volume":"331","author":"Liu","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.gastha.2026.100912_bib9","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/ANNALS-24-02870","article-title":"Trends in utilization of Glucose- and weight-lowering medications after tirzepatide approval in the United States: a population-based cohort study","volume":"178","author":"Ostrominski","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gastha.2026.100912_bib10","series-title":"National health and nutrition examination survey","author":"Johnson","year":"2013"},{"key":"10.1016\/j.gastha.2026.100912_bib11","series-title":"National health and nutrition examination Survey, 2017-March 2020 prepandemic file: Sample Design, Estimation, and Analytic Guidelines","first-page":"1","author":"Akinbami","year":"2022"},{"key":"10.1016\/j.gastha.2026.100912_bib12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/gut.2010.221382","article-title":"Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years","volume":"60","author":"Roulot","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.gastha.2026.100912_bib13","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/liv.15538","article-title":"Liver stiffness is associated with excess mortality in the general population driven by heart failure: the Rotterdam Study","volume":"43","author":"van Kleef","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2026.100912_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastha.2026.100912_bib15","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastha.2026.100912_bib16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: october 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2026.100912_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/HEP.0000000000001356","article-title":"Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction","volume":"83","author":"van Kleef","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2026.100912_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","article-title":"Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction","volume":"167","author":"van Kleef","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.100912_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2026.100912_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding John","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.gastha.2026.100912_bib22","first-page":"S181","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.gastha.2026.100912_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.sleh.2022.05.005","article-title":"Antimony and sleep health outcomes: nhanes 2009-2016","volume":"8","author":"Cavallino","year":"2022","journal-title":"Sleep Health"},{"key":"10.1016\/j.gastha.2026.100912_bib24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2026.100912_bib25","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/apt.14976","article-title":"Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany","volume":"48","author":"Labenz","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2026.100912_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100831","article-title":"Weight change is associated with metabolic liver health in a general population extending beyond weight loss targets of international guidelines","volume":"5","author":"van Kleef","year":"2026","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.gastha.2026.100912_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.gastha.2026.100912_bib28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.gastha.2026.100912_bib29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.gastha.2026.100912_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison Stephen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastha.2026.100912_bib31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.gastha.2026.100912_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021016","article-title":"The association of obesity with health insurance coverage and demographic characteristics: a statewide cross-sectional study","volume":"99","author":"Mylona","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastha.2026.100912_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.55222","article-title":"Factors associated with semaglutide initiation among adults with obesity","volume":"8","author":"Podolsky","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.gastha.2026.100912_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2337\/dci24-0091","article-title":"Compounded GLP-1 and dual GIP\/GLP-1 receptor agonists: a statement from the American Diabetes Association","volume":"48","author":"Neumiller","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.gastha.2026.100912_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108204","article-title":"Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes","volume":"36","author":"Limonte","year":"2022","journal-title":"J Diabetes Complications"},{"issue":"3","key":"10.1016\/j.gastha.2026.100912_bib36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastha.2026.100912_bib37","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.100912_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101547","article-title":"Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"51","author":"Cao","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.gastha.2026.100912_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2468-1253(24)00313-3","article-title":"Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study","volume":"10","author":"Lindfors","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:45:54Z","timestamp":1793403954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572326000336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572326000336"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100912","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Fibrotic Metabolic Dysfunction\u2013Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}],"article-number":"100912"}}